医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega Cell Viability Assay Designed Specifically for 3D Microtissue Culture

2014年06月11日 PM10:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

Promega Corporation launches a new assay validated for assessing the viability of cells in three-dimensional (3D) microtissue model systems. CellTiter-Glo® 3D Cell Viability Assay penetrates large 3D microtissue samples to provide more accurate determination of viable cells. The assay has been validated on a range of 3D microtissue model systems, generated using scaffold and scaffold-free systems. CellTiter-Glo 3D Assay uses the robust Ultra-Glo™ Recombinant Luciferase in a solution optimized to penetrate denser 3D microtissues for a complete release of ATP and accurate assessment of viability by luminescence detection.

CellTiter-Glo(R) 3D Cell Viability Assay better penetrates large 3D microtissue samples to provide m ...

CellTiter-Glo(R) 3D Cell Viability Assay better penetrates large 3D microtissue samples to provide more accurate determination of viable cells. (Photo: Business Wire)

Scientists have found that 3D microtissue cell culture models better reproduce the cell-to-cell and cell-to-matrix interactions occurring in living organisms, providing a more predictive in vitro experimental model system. Most, if not all commercial cell-based assays, including MTT, resazurin and current ATP assays, were developed using 2D monolayer models, are less effective on denser 3D microtissue models and cannot fully penetrate larger 3D microtissue spheroids.

“There is a clear need for cell viability assays validated for use in 3D microtissue culture. The novel chemistry of CellTiter-Glo 3D Reagent and the optimized protocol are designed specifically for these 3D model systems,” says Dr. Terry Riss, Senior Product Specialist at Promega.

The CellTiter-Glo 3D Assay has a simple add-mix-incubate-measure protocol that is completed in 30 minutes or less. The reagent includes optimized detergent concentration, ATPase inhibitors for protection of released ATP, proprietary thermostable Ultra-Glo™ Recombinant Luciferase and luciferin. CellTiter-Glo 3D Reagent acts on 3D microtissue cultures to release ATP, which is then consumed in the luciferase reaction to produce a stable glow-type luminescence. The amount of light produced correlates with the number of viable cells in culture. The simple protocol and high sensitivity of the assay make it amenable to higher throughput screening applications.

For more information or to sample the new CellTiter-Glo 3D Cell Viability Assay, see: www.promega.com/CTG3D.

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140611005070/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightreeが初のHME向け患者アプリを発表
  • Brightree发布面向居家医疗器械的首个患者App
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc